Atrial Fibrillation Clopidogrel Trial With Irbesartan for Prevention of Vascular Events - ACTIVE I


Since hypertension is one of the most prevalent risk factors for the development of atrial fibrillation (AF), the current trial sought to study the safety and efficacy of irbesartan, an angiotensin-receptor blocker (ARB), on the development of cardiovascular events and maintenance of sinus rhythm in patients with AF.